NEW YORK, Sept. 25, 2018 /PRNewswire/ -- This Persistence Market Research (PMR) report examines the 'Global Progressive Multifocal Leukoencephalopathy Treatment Market' for the period 2018–2026. The ...

A possible approach to the treatment of progressive multifocal leukoencephalopathy (PML) — a rare and often fatal viral disease of the brain that occurs in immunosuppressed patients and has no current ...

Patients with progressive multifocal leukoencephalopathy (PML), which is caused by the JC virus, can be successfully treated using cryopreserved BK-virus-specific T cells, new research suggests.

Paris, France, July 10, 2012 - Cytheris SA, a privately held clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, announces today that the European Commission has ...

The FDA has granted Orphan Drug designation to NT-I7 (efineptakin alfa; NeoImmuneTech) for the treatment of progressive multifocal leukoencephalopathy. The Food and Drug Administration (FDA) has ...

Paris, October 24, 2012 - Cytheris SA, a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, announces today that the US Food and Drug Administration (FDA) has ...